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Background: Non-adherence is widespread problem. Adherence is a crucial point for the success and the safe use
of therapies. The objective of this overview (review of reviews) was to identify factors that influence adherence in
chronic physical conditions.
Methods: A systematic literature search was performed in Medline and Embase (1990 to July 2013). Publications
were screened according to predefined inclusion criteria. The study quality was assessed using AMSTAR. Both
process steps were carried out independently by two reviewers. Relevant data on study characteristics and results
were extracted in piloted standardized tables by one reviewer and checked by a second. Data were synthesized
using a standardized quantitative approach by two reviewers.
Results: Seven systematic reviews were included. Higher education and employment seem to have a positive
effect on adherence. Ethnic minorities seem to be less adherent. Co-payments and higher medication cost seems
to have negative effect on adherence. In contrast financial status/income and marital status seem to have no influ-
ence on adherence. The effect of therapy related factors was mostly unclear or had no effect. Only the number of
different medications in heart failure patients showed the tendency of an effect. Indicators of regime complexity
showed consistently a negative effect direction. Duration of disease seems to have no effect on adherence. There is
the tendency that higher or middle age is associated with higher adherence. But in more than half of the reviews
the effect was unclear. There is no clear effect of physical as well as mental comorbidity. Only one review showed
the tendency of an effect for mental comorbidity. Also for gender the effect is not clear because the effect direction
was heterogenic between and within the systematic reviews.
Conclusion: The presented overview shows factors than can potentially have influence on adherence. Only for a
few factors the influence on adherence was consistent. Most factors showed heterogeneous results regarding
statistical significance and/or effect direction. However, belonging to an ethnic minority, unemployment and cost
for the patient for their medications showed consistently a negative effect on adherence which indicates that there
is a social gradient.
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Adherence, can be defined as “the extent to which a pa-
tient acts in accordance with the prescribed interval and
dose of a dosing regimen” [1]. Non-adherence is wide-
spread problem in chronic conditions [2,3]. Adherence
is not only a crucial point for the success, but also for
the safe and effective use of many therapies [4-6]. More-
over non-adherence can cause substantial costs [3]. In* Correspondence: Tim.Mathes@uni-wh.de
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unless otherwise stated.chronic conditions adherence is especially important be-
cause medication has to be taken for a long time.
Adherence is a multifactorial problem that can be in-
fluenced by various factors. The factors can be roughly
divided in the following five dimensions: Social and
economic, health care system, health condition, therapy
and patient [3]. Furthermore non-adherence can be
intentional (e.g. decided not to take because of adverse
events) and non-intentional (e.g. forgetfulness).
The objective was to identify factors that influence
adherence to oral medications in patients suffering fromLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of literature in this field it is difficult for researchers and
clinicians to know all relevant studies for all physical
chronic conditions. Thus, we decided to perform a re-
view of reviews (overview) which is a new form of evi-
dence synthesis to answer the research question. An
overview can provide a comprehensive picture of the
evidence while keeping the information flood manage-
able [7]. Furthermore we decided to focus on factors
that are not associated with the indication or therapy to
enhance universal applicability of the results.
Methods
Sources
A systematic literature search was performed in MED-
LINE (via Pubmed) and Embase (via Embase). The search
strategy combined various terms and medical subject
headings related to adherence, and oral medical medica-
tion (the full search strategies for each database are avail-
able in Additional file 1). The search was limited to a
publication date after 1990. The search was performed on
July the 15th 2013.
Study selection
To be eligible for this review the studies had to meet the
following inclusion criteria:
1. Patients: Adult patients with physical chronic
condition (i.e. studies that analysed only children,
patients with acute conditions or mental illness
were excluded).
2. Medication: Oral intake.
3. Exposure: Potentially adherence influencing factor
(exposure is not controlled by the investigator).
4. Outcome Adherence (right dose, right timing and/or
right frequency of intake).
5. Study type: Systematic review (definition: systematic
literature search in at least one electronic database
and assessment of risk of bias of included studies) of
quantitative studies.
6. Publication language: English or German.
It was decided to focus on factors unrelated to the
health care system (e.g. type of insurances), condition
(e.g. symptoms) and medication (e.g. side effects) i.e. fac-
tors that are strongly related to health care system, con-
dition or medications were excluded. For example side
effects or symptoms are strongly associated with the re-
spective medication disease respectively and can conse-
quently have different influence on adherence. The
purpose of focusing on disease and medication unrelated
factors was on the one hand to insure comparability,
consistency and clarity of results and on the other hand
to identify factors that are widely applicable in clinicalpractice. A preliminary unsystematic search was per-
formed to identify articles on adherence influencing fac-
tors. Based on identified articles a list of potential
adherence influencing factors was prepared and chosen
which factors are unrelated to the disease and therefore
should be included in the analysis. The decision to in-
clude a factor was made independently by two reviewers
and discussed until consensus in case of discrepancies.
The following factors were eligible: age, gender, ethnic
status, education, employment, financial status/income,
marital status/not living alone, social support, measure
of intake complexity (e.g. number of tablets, number of
medications, frequency of intake), duration of therapy,
duration of disease, comorbidity, co-payments, medica-
tion costs, insurance status (insured/not ensured).
Furthermore it was decided to include systematic re-
views only if the risk of bias of included primary studies
was assessed, documented and relatable to the respective
factor because an examination of the evidence for an ef-
fect of a potential adherence influencing factor is only
possible considering the validity of evidence of the pri-
mary studies.
Two reviewers performed the study selection inde-
pendently according to the inclusion criteria above.
Titles and abstracts of all articles were screened. The
full-texts of all potentially relevant articles were than ob-
tained and screened in detail. Any differences between
the reviewers were discussed until consensus. In addition
to identify grey literature the reference lists of all full-
texts were cross-checked and an additional search in
Google scholar performed.
Methodological quality assessment
The methodological quality of included studies was
assessed using the AMSTAR instrument that was found
to be valid and reliable to assess SRs [8,9]. Each assess-
ment question was rated with “yes”, “no”, “unclear” or
“not applicable”. The instrument was applied independ-
ently by two reviewers. Disagreements were resolved in
a discussion. The question “was the scientific quality of
the included studies assessed and documented” was
skipped because we formulated quality assessment of
included studies as inclusion criterion (see inclusion
criterion 5).
Data extraction and synthesis
Data were extracted by one reviewer in standardized
summary tables and were verified by a second reviewer.
Any disagreements were discussed till consensus. For
each systematic review, characteristics were extracted on
the condition/medication (marked bold), inclusion and
exclusion criteria for primary studies (only other than
our applied inclusion criteria) and search period limits.
Results were extracted according to the type of evidence
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were abstracted by modified vote counting [10]. This
contained data to the effect direction, all comparisons
showing this effect direction, statistically significant
comparisons showing this effect direction and total
number of comparisons for this factor. This method has
been suggested for presenting results of qualitative syn-
thesis, overcoming problems arising when simple vote
counting is used by relying either on the number of
comparisons with a positive direction of effect or the
number of comparisons reaching statistical significance.
For all meta-analyses, pooled effect sizes and measures
with confidence intervals and test and measure for
statistical heterogeneity were extracted. All data in the
tables were commutated so that the influence on adher-
ence refers throughout to an increase of the respective
factor independently whether the factor is positive (e.g.
educational level) or negative (adverse events). A p-
level of less than 0.05 was considered statistical signifi-
cant. Overlaps (multiple included primary studies) were
assessed in case of multiple systematic reviews on the
same indication.
For all factors a summary evaluation of the influence
was made. Two reviewers rated the evidence for an effect,
considering the number of included systematic reviews
for a comparison, the effect direction, the significance and
consistency (within and between systematic reviews) of re-
sults, the methodological quality of systematic reviews and
the methodological quality/risk of bias of included primary
studies. If only one high quality study was included in a
comparison that showed a statistical significant positive ef-
fect for a certain factor, this was rated as tendency for a
positive effect. Discrepant judgments were discussed until
consensus.Figure 1 Flow-chart of study selection.Results
Description of included systematic reviews
The electronic literature search resulted in 1604 hits
after duplet removal (EndNote ×5). Of these 72 titles
and abstracts seemed potential relevant and full-text ver-
sions of the publications were screened in detail. Seven
studies met all inclusion criteria and were finally in-
cluded in this overview [11-17]. The process of study se-
lection is illustrated in the flowchart (see Figure 1). Most
systematic reviews were excluded because a risk of bias
assessment was not performed or the quality of evidence
was not attributable to the influencing factors (inclusion
criteria 5).
The included systematic reviews assessed adherence
influencing factors in the following conditions/medica-
tions; chronic malignant pain, Parkinson disease, heart
failure, inflammatory arthritis, prophylactic treatment
of hemophilia A or B, intake of oral anti-cancer agents
[11-15,17]. Sinoott et. al did not restrict the condition or
medication but included all studies that analysed public
insured patients which were exposed to co-payments for
medications [16]. Overlaps were not assessed, because
all included systematic reviews were on different indica-
tions. The characteristics of the included systematic re-
views are presented in Table 1.
Methodological quality of included systematic reviews
Overall the quality of included systematic reviews was
moderate to high One systematic review satisfied all
quality criteria [16] and two did not fulfil only one qual-
ity criterion [12,17]. At most three items were not an-
swered with “no” or “unclear” (three studies [11,14,15]).
In three systematic reviews the study selection and/or
data extraction was not performed in duplicate or the
Table 1 Study characteristics
Study Search period Inclusion criteria*
Broekmans [11] Not limited – 12/2006 Adult patients with chronic non-malignant pain
Adult patients with prescribed pain medication
Original research
Daley [12] Not limited – 01/2012 Patients with Parkinson




Oosterom-Calo [13] Not limited – 08/2010 ≥50% heart failure patients
Quantitative results were reported
Studies of at least fair quality




Pasma [14] Not limited – 02/2011 Inflammatory arthritis patients
Used a reproducible definition or validated instrument to measure adherence
Provided a statistical measure to reflect the strength of the association between
the determinant and adherence
No letters, editorials, reviews, RCTs, case reports, qualitative studies and opinion articles
Schrijvers [15] Not reported – 15/2012 Haemophilia A or B
Prophylactic treatment
All age groups
Sinnott [16] 1946 – 09/2012 Participants received healthcare from a public insurance scheme
Comparator group was the same population/similar population who either didn’t pay copayments
or experienced no increase in copayment
The intervention was copayment; either an increase in an existing copayment or the
introduction of a copayment (no other types of cost-sharing, for example co-insurance)
Studies included were randomised controlled trials, controlled before and after studies,
interrupted time series designs, repeated measures designs, and cohort designs
Verbrugghe [17] NR Oral anti-cancer drugs
Age≥ 18
Strong or moderate methodological quality
Written in English, French, German or Dutch
Original research articles published between 1990 and April 2012
Studies not conducted in developing countries
All study designs
*Indication & medication marked bold.
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tion [11,14,15]. The most frequent flaw was that a list of
excluded studies was not provided. The assessment
questions relating to combing findings and publication
bias were rated as not applicable in 6 studies because
a quantitative data-synthesis was not performed. The quality
of each systematic review is presented in Table 2.Effect of adherence influencing factors
The following factors were included in the analysis: age,
comorbidity, co-payments, duration of disease, duration
of therapy, education, ethnic status, gender, regime com-
plexity (e.g. number of daily intake, number of tablets,
frequency of intake, daytime of intake), marital status
(including domestic partnerships), medication costs,























Broekmans [11] + ? + + - + + O O -
Daley [12] + + + + - + + O O +
Oosterom-Calo [13] + + - + - + + O O +
Pasma [14] + ? + + - + + O O -
Schrijvers [15] + - + ? - + + O O +
Sinnott [16] + + + + + + + + + +
Verbrugghe [17] + + + + - + + O O +
+ = yes; − = no; O = not applicable; ? = unclear.
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come, employment.
The results of individual systematic reviews are pre-
sented in Additional file 2 and the evidence synthesis of
individual systematic reviews is presented in Table 3.Social and economic factors
The evidence for effect of education was mostly judged
as unclear. Only in chronic malignant pain there is a
tendency that education has effect on adherence [11].
However the effect direction was not reported in this
systematic review. In the systematic reviews that re-
ported effect direction, education showed a positive in-
fluence on adherence [13,17].
Employment was only analysed in the systematic re-
view on inflammatory arthritis [14]. There is a tendency
of effect but the effect direction was not reported.
In Parkinson diseases there is the tendency that ethnic
minorities are less adherent [12]. In inflammatory arth-
ritis whites seem to be more adherent [14].
Financial status seems to have no effect on adherence.
The three systematic reviews that analysed this outcome
showed no effect, the tendency of no effect, or unclear
effect respectively [12,13,17].
The effect of social support was unclear in both sys-
tematic reviews that analysed this exposure [13,14].Therapy related factors
Duration of therapy was only analysed in the systematic
review on oral anticancer agents [17]. The effect direction
was negative. But the evidence for effect was unclear.
The effect direction of frequency of intake was nega-
tive in one primary study on patients with Parkinson dis-
eases [12]. However, the study was not statistical
significant. There is no effect of frequency of intake on
adherence in patients with heart failure or inflammatory
arthritis patients [14].
The effect of tablets taken per day in heart failure
patients is unclear, because one of the two studies thatanalysed this factor was statistical significant and one was
not. Moreover effect direction was not reported [13].
Most of the systematic reviews that analysed intake of
different medications showed a negative effect on adher-
ence (Parkinson, oral anticancer therapy, inflammatory
arthritis) [12,14,17]. In patients with chronic malignant
pain the effect direction was heterogenic for this factor
[11]. For taking different medications there was some
evidence for effect in heart failure patients. But effect
direction was unclear [13].
Taking medications at meals showed a positive
effect direction on adherence in patients taking oral
anticancer agents. The evidence for effect was un-
clear [17].
Duration of diseases seems to have no influence on ad-
herence in patients with chronic malignant pain and ten-
dentially not in patients with inflammatory arthritis
[11,14]. For patients taking oral anticancer agents the ef-
fect direction was negative, but evidence for effect was
unclear [17].
Patient related factors
With one exception [17], all studies showed a positive
effect of higher age or middle age on adherence.
There was a tendency for effect in patients with Par-
kinson and heart failure [12,13]. In patients with in-
flammatory arthritis the effect of higher age was
unclear. Patients aged between 35–56 showed higher
adherence than other age groups in one study [14]. For
the other indications (chronic malignant pain, hemophilia,
oral anticancer therapy) the evidence of effect was unclear
[11,15,17].
The evidence for effect of comorbidity was mostly un-
clear [12-14]. Only in heart failure patients there was the
tendency of negative effect of mental comorbidities [13].
The effect direction of gender was heterogeneous in
patients with heart failure and patients on oral anti-
cancer therapy [13,17]. In patients with chronic malig-
nant pain there was the tendency of higher adherence in
women [11].
Table 3 Evidence synthesis
Factor Relationship
Indication/therapy Effect direction Evidence for effect
Social and economic
Education Chronic pain O +
Parkinson ↑ O
Heart failure* O O
Oral cancer therapy ↑ O
Employed Inflammatory arthritis O +
Ethnic status Parkinson Ethnic minorities < others +
Inflammatory arthritis White > others +
Oral cancer therapy Non-white > others O
Financial status/income Parkinson ↑ -
Heart failure* O --
Oral cancer therapy ↑ O
Married/not living alone Parkinson ↑ -
Oral cancer therapy ↕ O
Social support Heart failure* ↕ O
Inflammatory arthritis ↑ O
Therapy related
Duration of therapy Oral cancer therapy ↓ O
Frequency of intake Parkinson ↓ O
Heart failure* O --
Inflammatory arthritis O --
Number of pills taken per day Heart failure* O O
Different medications Chronic pain ↕ O
Parkinson ↓ O
Inflammatory arthritis ↓ O
Oral cancer therapy ↓ O
Heart failure* O +
Taking medication at meals Oral cancer therapy ↑ O
Disease related
Duration of disease Chronic pain O --
Inflammatory arthritis ↓ -
Oral cancer therapy ↓ O
Patient related
Age Chronic pain ↑ O
Parkinson ↑ +
Heart failure* ↑ +
35-56 > others +
Inflammatory arthritis ↑ O
55-64 > others +
Hemophilia ↑ O
Oral cancer therapy ↕ O
Comorbidity (not specified) Inflammatory arthritis ↑ O
Comorbidity (physical) Heart failure* ↕ O
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Table 3 Evidence synthesis (Continued)
Comorbidity (mental) Parkinson ↓ O
Heart failure* ↓ +
Gender (female) Chronic pain ↑ +
Heart failure* ↕ O
Oral cancer therapy ↕ O
Health care system factors
Co-payments Inflammatory arthritis ↓ +
Not restricted ↓ ++
Oral cancer therapy ↓ O
Medication costs Inflammatory arthritis ↓ +
Oral cancer therapy ↓ O
Effect direction.
↑: positive (all studies showed a positive effect on adherence); ↓: negative (all studies showed a negative effect on adherence); ↕: heterogenic (i.e. at least one
study showed a contrary effect direction); O: unclear reported/ not reported.
Evidence for effect.
++: clear effect.
+: tendency of effect.
–: no effect.
-: tendency of no effect.
O: unclear effect.
*Inclusion criteria for studies: ≥50% of population are heart failure patients.
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Co-payments and medication costs showed a negative
effect direction in all systematic reviews. For both fac-
tors there was a tendency of effect in inflammatory
arthritis patients and unclear effect in patients taking
oral anticancer agents [14,17]. The meta-analysis on
co-payments in public insurance systems showed a clear
negative effect [16].
Discussion
Seven relevant systematic reviews could be identified that
satisfied all inclusion criteria. The quality of the systematic
reviews was moderate to high.
Of the social economic factors higher education and
employment seem to have a positive effect on adherence.
Moreover ethnic minorities seem to be less adherent. In
contrast financial status/income and marital status seem
to have no influence on adherence. The effect of therapy
related factors was mostly unclear or had no effect. Only
the number of different medications in heart failure pa-
tients showed the tendency of an effect. However indica-
tors of regime complexity showed consistently a negative
effect direction. Duration of disease seems to have no ef-
fect on adherence. There is the tendency that higher or
middle age is associated with higher adherence. But in
more than half of the reviews the effect was unclear. There
is no clear effect of physical as well as mental comorbidity.
Only one review showed the tendency of an effect for
mental comorbidity. Also for gender the effect is not
clear because the effect direction was heterogenic be-
tween and within the systematic reviews. Co-paymentsand higher medication cost seems to have negative
effect on adherence.
The results of the excluded systematic reviews on
other chronic conditions are broadly in accordance with
the results of the presented analysis. However most of
these did not assess the risk of bias of included primary
studies and results could therefore not be assessed sys-
tematically [18-23].
Although the quality of systematic reviews was moder-
ate to high, there is a loss of information in our overview
because of poor reporting in the systematic reviews. Thus,
we often had to rate the evidence for effect as unclear not
because of a “real” lack of evidence. For example it was
not possible to include the effect size and number of in-
cluded patients in the evidence synthesis because with one
exception [16] none of the studies provide information on
these. It appears that some studies report only significant
comparisons. These impression is also in accordance with
prior research [24]. For such reviews that did not mention
the total number of comparisons for a certain factor but
only the statistical significant comparisons it is impos-
sible to make a summary estimation of effect. Conse-
quently the evidence for effect in the systematic review
of Daley et al. and Verbrugghe et al. had to be judged as
unclear, throughout [12,17].
Another limitation is that there were no information
on adjustments of analysis, although confounding is a
major problem in observational study designs [25,26]. So
data had to be extracted irrespective of the adjustments
with might cause some of the heterogeneity of results.
Furthermore no information can be derived on the
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the effect of co-payments and medication costs is stron-
ger in low income groups cannot be proven.
In continuous variables source of heterogeneity are
probably the different categorizations. For example studies
that analysed age with different categorizations showed
higher adherence in the middle aged. In contrast studies
that analysed age as linear showed often no statistical sig-
nificance results and effect directions were partly even
conflicting. Also for the factors that describe the complex-
ity of intake regime different definitions and categori-
zations are probably a source for heterogeneity of results
(e.g. frequency of intake, number of different medications).
For such factors a well-chosen categorization (e.g. by test-
ing different categorizations), definition and clear report-
ing of analysis is warranted for a substantial evaluation.
In the overview symptomatic as well as asymptomatic
conditions were considered. Research has shown, prob-
ably because of the lower perceived importance of taking
medications correctly that adherence is lower in asymp-
tomatic conditions than in symptomatic conditions
[27,28]. The differences in adherence might be another
reason for between study heterogeneity that is not con-
trolled for.
A further probable source for heterogeneity is that
there is no differentiation between intentional and non-
intentional adherence. Indeed prior research revealed
that non-adherence is mostly non-intentional [29]. How-
ever, the influence of an factor can differ between
intentional and non-intentional adherence [30].
The overview has some methodological limitations.
Firstly there is a risk for publication bias because we did
not search other languages than English and German.
Secondly the overview focuses only on therapy imple-
mentation. I.e. initiation and discontinuation of therapy
were not considered [31]. Thirdly we assessed the in-
cluded systematic reviews of prognostic factors with
AMSTAR, which was originally developed for the qual-
ity assessment of systematic reviews of health interven-
tions and which was only validated in randomised
controlled trials.
These review aimed to provide a comprehensive over-
view of factors that can have influence on adherence for a
wide variety of indications. Surprisingly, despite the mass
of literature on adherence we could identify only system-
atic reviews on seven different chronic physical conditions
that satisfied all inclusion criteria. The results possibly can
be transferred to other conditions because we considered
only condition and therapy unrelated factors in physical
chronic conditions. This suggestion is confirmed by the re-
sults of systematic reviews on other chronic conditions
[18-23]. However, it should be considered in the interpret-
ation of data that the generalizability is limited because of
this fact.Only condition and therapy unrelated factors were
analysed in this overview. There are also factors that are
related to the respective condition (e.g. concomitant
medications, symptoms) or therapy (e.g. side effects.
complex treatment regimens) [7,27]. In some conditions
such factors may even be the most important cause of
non-adherence. Moreover we analysed only selected fac-
tors. There are other therapy and condition unrelated
factors that might have also an effect on adherence. E.g.
for the physician- patient relationship, health literacy
and positive beliefs about medication a positive effect on
adherence is described for some chronic conditions.
Again for long distance from treatment setting, forget-
fulness and clinical asymptomatic course/disease mostly
a negative influence on adherence is reported [3].
Most determinates of social status showed an effect on
adherence. Apparently lower social status has a negative
effect on adherence. This knowledge can contribute to
identify vulnerable groups for non-adherence that are po-
tential candidates for programs to enhance adherence [32].
The knowledge of adherence influencing factors can fur-
thermore support the development of interventions and
public health programs that are tailored to specific patient
needs and that attempt to enhance adherence by reducing
adherence barriers (e.g. counselling interventions tailored
to education status, reduction of co-payments) [33].
Moreover the knowledge on adherence influencing fac-
tors can contribute to the development of risk factor based
screening tools. Similar instruments have been developed
for some indications [34].
Conclusion
The presented overview indicates factors than can
potentially have influence on adherence. Only for a few
factors the influence on adherence was consistent.
Belonging to an ethnic minority, unemployment and
cost for the patient for their medications showed a negative
effect on adherence which indicates that there is a social
gradient. This indicates that future programs to enhance
adherence should focus on social disadvantaged groups.
For example a possibility could be to reduce co-payments
for vulnerable groups.
Most of the other analysed factors showed heteroge-
neous results regarding statistical significance and/or
effect direction. The results of this overview should
therefore be considered as indication for factors that can
have an influence on adherence in chronic physical con-
ditions. To be of sufficient significance to make deci-
sions in clinical practice, the factors have to be evaluated
in detail for the specific context of the decision.
Further systematic reviews that assesses the risk of
bias of included studies to allow an estimation of the
validity of results and that are transparently reported are
needed. Especially on the factors for that the evidence
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